

Eva Dombi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4944475/publications.pdf>

Version: 2024-02-01

61
papers

3,164
citations

172457

29
h-index

161849

54
g-index

61
all docs

61
docs citations

61
times ranked

3136
citing authors

#	ARTICLE	IF	CITATIONS
1	Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. <i>New England Journal of Medicine</i> , 2016, 375, 2550-2560.	27.0	486
2	Selumetinib in Children with Inoperable Plexiform Neurofibromas. <i>New England Journal of Medicine</i> , 2020, 382, 1430-1442.	27.0	360
3	Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. <i>Neuro-Oncology</i> , 2008, 10, 593-598.	1.2	200
4	Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study. <i>Neuro-Oncology</i> , 2015, 17, 596-603.	1.2	118
5	Recommendations for imaging tumor response in neurofibromatosis clinical trials. <i>Neurology</i> , 2013, 81, S33-40.	1.1	107
6	Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. <i>Acta Neuropathologica</i> , 2013, 125, 159-168.	7.7	104
7	Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 75.	2.7	99
8	Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. <i>Journal of Clinical Oncology</i> , 2016, 34, 1669-1675.	1.6	92
9	The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. <i>Neuro-Oncology</i> , 2018, 20, 818-825.	1.2	83
10	Radiation Therapy in Management of Sporadic and Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors. <i>Frontiers in Oncology</i> , 2014, 4, 324.	2.8	80
11	Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. <i>Computerized Medical Imaging and Graphics</i> , 2004, 28, 257-265.	5.8	75
12	Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 2103-2113.	1.2	72
13	Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas. <i>Neuro-Oncology</i> , 2019, 21, 981-992.	1.2	69
14	Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1. <i>Ophthalmology</i> , 2017, 124, 123-132.	5.2	68
15	Current whole-body MRI applications in the neurofibromatoses. <i>Neurology</i> , 2016, 87, S31-9.	1.1	65
16	Preclinical testing of Sorafenib and RAD001 in the <i>Nf1</i> ^{flox/flox} ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. <i>Pediatric Blood and Cancer</i> , 2012, 58, 173-180.	1.5	60
17	Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1709-1716.	1.5	59
18	Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome. <i>American Journal of Human Genetics</i> , 2019, 104, 484-491.	6.2	56

#	ARTICLE	IF	CITATIONS
19	Insertional Mutagenesis Identifies a STAT3/Arid1b/β ² -catenin Pathway Driving Neurofibroma Initiation. Cell Reports, 2016, 14, 1979-1990.	6.4	55
20	Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro-Oncology, 2018, 20, 1643-1651.	1.2	54
21	NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Journal of Clinical Oncology, 2021, 39, 797-806.	1.6	54
22	¹⁸ F-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). Pediatric Blood and Cancer, 2013, 60, 59-64.	1.5	52
23	Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. Communications Biology, 2018, 1, 158.	4.4	49
24	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nature Medicine, 2021, 27, 165-173.	30.7	46
25	Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). Sarcoma, 2019, 2019, 1-8.	1.3	45
26	Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro-Oncology, 2017, 19, now158.	1.2	41
27	Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions. Neuro-Oncology, 2020, 22, 1368-1378.	1.2	37
28	Current status of MEK inhibitors in the treatment of plexiform neurofibromas. Child's Nervous System, 2020, 36, 2443-2452.	1.1	33
29	Characterization of spinal findings in children and adults with neurofibromatosis type 1 enrolled in a natural history study using magnetic resonance imaging. Journal of Neuro-Oncology, 2015, 121, 209-215.	2.9	31
30	MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro-Oncology, 2022, 24, 1845-1856.	1.2	30
31	Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro-Oncology, 2022, 24, 1827-1844.	1.2	29
32	Puberty and Plexiform Neurofibroma Tumor Growth in Patients with Neurofibromatosis Type I. Journal of Pediatrics, 2014, 164, 620-624.	1.8	28
33	SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. Journal of Clinical Oncology, 2018, 36, 10503-10503.	1.6	28
34	Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. Clinical Cancer Research, 2018, 24, 753-765.	7.0	26
35	<i>Cdkn2a</i> Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST. Cancer Research, 2020, 80, 4720-4730.	0.9	25
36	Cxcr3-expressing leukocytes are necessary for neurofibroma formation in mice. JCI Insight, 2019, 4, .	5.0	21

#	ARTICLE	IF	CITATIONS
37	Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1. <i>Journal of Neurosurgery</i> , 2020, 133, 1516-1526.	1.6	20
38	Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. , 2021, 9, e003238.		19
39	SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11053-11053.	1.6	19
40	Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1. <i>Academic Radiology</i> , 2018, 25, 144-152.	2.5	17
41	The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa095.	0.7	15
42	NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. <i>Neuro-Oncology</i> , 2018, 20, i143-i143.	1.2	14
43	Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. <i>Neuro-Oncology</i> , 2022, 24, 1978-1988.	1.2	14
44	A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2019, 25, 6302-6308.	7.0	13
45	Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type 1-Related Plexiform Neurofibromas. <i>Clinical Cancer Research</i> , 2020, 26, 6112-6121.	7.0	13
46	A molecular basis for neurofibroma-associated skeletal manifestations in NF1. <i>Genetics in Medicine</i> , 2020, 22, 1786-1793.	2.4	12
47	MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK. <i>Oncogene</i> , 2021, 40, 951-963.	5.9	12
48	Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. <i>Journal of Clinical Oncology</i> , 2020, 38, 3612-3612.	1.6	12
49	Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS). <i>Pediatric Blood and Cancer</i> , 2019, 66, e27987.	1.5	11
50	RUNX represses <i>Pmp22</i> to drive neurofibromagenesis. <i>Science Advances</i> , 2019, 5, eaau8389.	10.3	11
51	Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1. <i>Neurology</i> , 2021, 97, S111-S119.	1.1	6
52	Are Some Randomized Clinical Trials Impossible?. <i>Journal of Pediatric Orthopaedics</i> , 2021, 41, e90-e93.	1.2	5
53	Fascicle Sparing Capsular Resections of Atypical Neurofibromas in Neurofibromatosis 1. <i>Neurosurgery</i> , 2019, 66, .	1.1	3
54	Feasibility of magnetic resonance-guided high-intensity focused ultrasound treatment targeting distinct nodular lesions in neurofibromatosis type 1. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab116.	0.7	2

#	ARTICLE	IF	CITATIONS
55	Atypical neurofibromas in neurofibromatosis 1 (NF1): Clinical, imaging and pathologic characteristics.. Journal of Clinical Oncology, 2016, 34, 11035-11035.	1.6	2
56	Outcomes of children with hereditary medullary thyroid carcinoma (MTC) treated with vandetanib.. Journal of Clinical Oncology, 2017, 35, 10540-10540.	1.6	2
57	Results of a phase I trial of ganitumab plus dasatinib in patients with rhabdomyosarcoma (RMS).. Journal of Clinical Oncology, 2022, 40, 11561-11561.	1.6	2
58	RARE-07. THE EFFECT OF SELUMETINIB ON SPINAL NEUROFIBROMAS IN PATIENTS WITH NF1. Neuro-Oncology, 2018, 20, vi237-vi237.	1.2	1
59	Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).. Journal of Clinical Oncology, 2016, 34, TPS2596-TPS2596.	1.6	1
60	Cediranib phase II study in children with metastatic alveolar soft part sarcoma (ASPS).. Journal of Clinical Oncology, 2018, 36, 10540-10540.	1.6	1
61	Phase II Study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. Journal of Clinical Oncology, 2016, 34, TPS10586-TPS10586.	1.6	0